+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 84Years
All Genders
ID05717179

Evaluating Ultrasound-Guided Treatment Decisions Versus Clinical Assessment Alone in Adults With Rheumatoid Arthritis Using a Treat-to-Target Approach

Led by Italian Society for Rheumatology · Updated on 2026-11-04

158

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatment strategies for patients diagnosed with Rheumatoid Arthritis RA who have moderate or high disease activity despite ongoing conventional or biologic therapies. The study aims to compare a standard clinical decision approach with a combined clinical and ultrasound-guided treatment decision to see which better achieves low disease activity or remission by week 24. This randomized, multicenter clinical trial intends to assess whether using ultrasound can improve treatment outcomes in RA. Participants are randomly assigned to one of two groups the control group receives a new course of biologic or targeted synthetic DMARDs with or without conventional DMARDs, with therapy adjustments based on clinical assessment at 12 weeks. The experimental group receives similar treatment but with additional ultrasound evaluations of 44 joints at baseline, 12, 24, and 48 weeks to guide treatment decisions. If inflammation is detected by both clinical and ultrasound assessment, treatment is adjusted accordingly otherwise, pain management is stepped up while background therapy continues. During the 48-week active phase, participants undergo multiple assessments including clinical disease activity scores, ultrasound imaging, and various patient-reported outcomes such as pain scales, fatigue, and quality of life questionnaires. Laboratory tests like ESR and CRP are also monitored. The study tracks changes in joint counts, remission rates, and physical function at regular intervals, with primary outcomes evaluated at week 24. Safety and treatment efficacy are closely monitored throughout, with total study duration planned for up to 72 months including recruitment and follow-up.

CONDITIONS

Brief Title

Ultrasound to Guide Treatment Decisions in Patients With Rheumatoid Arthritis According to a T2T Approach

Research Team

C

Christian Dejaco, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here